Literature DB >> 10705225

IL-4 induces eotaxin production in corneal keratocytes but not in epithelial cells.

K Fukagawa1, T Nakajima, H Saito, K Tsubota, S Shimmura, M Natori, K Hirai.   

Abstract

BACKGROUND: In severe allergic eye diseases, the breakdown of epithelial barrier function can lead to severe corneal damage such as erosions or ulcers which often resist treatment. Although eosinophils are thought to play a crucial role in corneal tissue damage in severe ocular allergy, the mechanisms of eosinophil recruitment to the cornea has not been fully clarified. Eotaxin has been found in tears of severe allergic patients with corneal ulcer. In this study, we investigated whether the Th2 cytokine interleukin-4 (IL-4) induces eotaxin production in human corneal epithelial cells and keratocytes.
METHODS: Primary cultures of human corneal epithelial cells and keratocytes were incubated with IL-4 and/or TNF-alpha for 48 h. Released eotaxin was measured by ELISA, and the eotaxin proteins were visualized by immunocytochemistry. Eotaxin mRNA expression in cultured cells was analyzed by RT-PCR.
RESULTS: IL-4 induced eotaxin production in keratocytes in a dose- and time-dependent manner which was enhanced by TNF-alpha. There was no detectable eotaxin produced by corneal epithelial cells (<5 pg/ml). The cytoplasm of keratocytes incubated with IL-4 stained positively against anti-eotaxin antibodies, while eotaxin mRNA was detected in keratocytes incubated with IL-4.
CONCLUSIONS: Human corneal keratocytes, but not epithelial cells, are capable of producing eotaxin by stimulation with IL-4. Our results suggest that eotaxin production in keratocytes induced by IL-4 may play an important role in eosinophil recruitment to corneal ulcers in allergic ocular disease. Eotaxin production by keratocytes may explain the severity of allergic disease involving the corneal stroma. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10705225     DOI: 10.1159/000024310

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  7 in total

1.  Relationship between tear eotaxin-2 and MMP-9 with ocular allergy and corneal topography in keratoconus patients.

Authors:  Melek Mutlu; Ozge Sarac; Nurullah Cağıl; Gamze Avcıoğlu
Journal:  Int Ophthalmol       Date:  2019-07-30       Impact factor: 2.031

2.  Local allergic conjunctivitis: a phenotype of allergic conjunctivitis.

Authors:  Yasuo Yamana; Ken Fukuda; Ryota Ko; Eiichi Uchio
Journal:  Int Ophthalmol       Date:  2019-05-15       Impact factor: 2.031

Review 3.  Epithelial cells in ocular allergy.

Authors:  Murat Irkeç; Banu Bozkurt
Journal:  Curr Allergy Asthma Rep       Date:  2003-07       Impact factor: 4.806

4.  Clinical Usefulness of Monitoring Expression Levels of CCL24 (Eotaxin-2) mRNA on the Ocular Surface in Patients with Vernal Keratoconjunctivitis and Atopic Keratoconjunctivitis.

Authors:  Yukiko Shiraki; Jun Shoji; Noriko Inada
Journal:  J Ophthalmol       Date:  2016-09-18       Impact factor: 1.909

5.  Elevated levels of prostaglandin E2 in the tears of patients with severe allergic conjunctivitis and primary cultured conjunctival cells are suppressed by ketotifen and dexamethasone.

Authors:  Ryutaro Yamanishi; Naoko Okada; Eisuke Shimizu; Hiroshi Fujishima
Journal:  BMJ Open Ophthalmol       Date:  2021-01-25

6.  Expression of IL-33 in ocular surface epithelium induces atopic keratoconjunctivitis with activation of group 2 innate lymphoid cells in mice.

Authors:  Yasutomo Imai; Yuka Hosotani; Hiroto Ishikawa; Koubun Yasuda; Makoto Nagai; Orie Jitsukawa; Fumi Gomi; Kenji Nakanishi; Tomohiro Yoshimoto; Takahiro Nakamura; Kiyofumi Yamanishi
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

Review 7.  Role of Damage-Associated Molecular Patterns (DAMPs/Alarmins) in Severe Ocular Allergic Diseases.

Authors:  Ken Fukuda; Waka Ishida; Tatsuma Kishimoto; Isana Nakajima; Yusaku Miura; Tamaki Sumi; Kenji Yamashiro
Journal:  Cells       Date:  2022-03-20       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.